Abstracts tagged "lupus nephritis and outcome measures"

Abstract Number: 1945 • 2018 ACR/ARHP Annual Meeting
Early Prediction of Long-Term Renal Outcomes in Lupus Nephritis Using Hazard Index Equations
Farah Tamirou¹, Meggan Mackay², Maria Dall'Era³, Joanna Fishbein⁴, Kenneth C. Kalunian⁵, Brad H. Rovin⁶ and Frédéric A. Houssiau⁷, ¹Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³University of California, San Francisco, San Francisco, CA, ⁴The Feinstein Institute for Medical Research, New York, NY, ⁵University of California San Diego, San Diego, CA, ⁶Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ⁷Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Early endpoints predicting long-term outcome in lupus nephritis (LN), which could be used as outcome measures in clinical trials, are still debated. Recently, a…
Abstract Number: 967 • 2016 ACR/ARHP Annual Meeting
Using a Hazard Index Tool Based on Short Term Renal Parameters to Predict Long Term Outcomes in Lupus Nephritis: A Novel Way to Assess New Therapies
Meggan Mackay¹, Joanna Fishbein², Maria Dall'Era³, Kenneth Kalunian⁴, Martin Lesser⁵ and Brad H. Rovin⁶, ¹Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ²Biostatistics Unit, The Feinstein Institute for Medical Research, Manhasset, NY, ³Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁵Biostatistics, Feinstein Institute for Medical Reasearch, Manhasset, NY, ⁶Ohio State University Medical Center, Columbus, OH
Background/Purpose: Variability in response criteria for lupus nephritis (LN) clinical trials (CTs) has compromised the legitimacy and generalizability of CT results, primarily because short term…
Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Nicolas Wisniacki¹, Chris Stebbins², Jadwiga Bienkowska³, Susan Gawlak², Donald Bennett⁴, Yuhong Xiang⁵, Andrea Dearth⁶, Linda C. Burkly⁷, Ann Ranger⁶, Carrie Wager⁵, Laurence S. Magder⁸ and Michelle Petri⁹, ¹Medical Research, Biogen Idec, Maidenhead, United Kingdom, ²Translational Medicine, Biogen Idec, Cambridge, MA, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biostatistics, Biogen idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec Inc, Cambridge, MA, ⁷Biogen Idec, Cambridge, MA, ⁸Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…
Abstract Number: 612 • 2013 ACR/ARHP Annual Meeting
Increased Expression Of Membrane Endothelial Protein C Receptor Associates With Poor Response In Lupus Nephritis Independent Of Chronicity Index
Barbara Mendez¹, Ming Wu², Dominick Santoriello², Laura Barisoni³, Peter M. Izmirly¹, Jill P. Buyon¹ and Robert M. Clancy⁴, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pathology, New York University School of Medicine, New York, NY, ³Pathology, University of Miami Hospital, Miami, FL, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: While a consensus is that a high chronicity index (CI) is associated with a greater risk for progression to renal failure in lupus nephritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].